

# *roX* RNAs Are Required for Increased Expression of X-Linked Genes in *Drosophila melanogaster* Males

Xinxian Deng<sup>\*,†</sup> and Victoria H. Meller<sup>\*,1</sup>

<sup>\*</sup>Department of Biological Science, Wayne State University, Detroit, Michigan 48202 and <sup>†</sup>Department of Biology, Tufts University, Medford, Massachusetts 02155

Manuscript received August 8, 2006

Accepted for publication September 29, 2006

## ABSTRACT

The male-specific lethal (MSL) ribonucleoprotein complex is necessary for equalization of X:A expression levels in *Drosophila* males, which have a single X chromosome. It binds selectively to the male X chromosome and directs acetylation of histone H4 at lysine 16 (H4Ac16), a modification linked to elevated transcription. *roX1* and *roX2* noncoding RNAs are essential but redundant components of this complex. Simultaneous removal of both *roX* RNAs reduces X localization of the MSL proteins and permits their ectopic binding to autosomal sites and the chromocenter. However, the MSL proteins still colocalize, and low levels of H4Ac16 are detected at ectopic sites of MSL binding and residual sites on the X chromosome of *roX1<sup>-</sup>roX2<sup>-</sup>* males. Microarray analysis was performed to reveal the effect of *roX1* and *roX2* elimination on X-linked and autosomal gene expression. Expression of the X chromosome is decreased by 26% in *roX1<sup>-</sup>roX2<sup>-</sup>* male larvae. Enhanced expression could not be detected at autosomal sites of MSL binding in *roX1<sup>-</sup>roX2<sup>-</sup>* males. These results implicate failure to compensate X-linked genes, rather than inappropriate upregulation of autosomal genes at ectopic sites of MSL binding, as the primary cause of male lethality upon loss of *roX* RNAs.

**D**ROSOPHILA males have one X chromosome and two sets of autosomes (A). The imbalance in X:A gene dosage is addressed by the male-specific lethal (MSL) complex that binds to hundreds of sites along the male X chromosome. While there is general agreement that this complex is responsible for dosage compensation, disagreement about how compensation is accomplished remains (BIRCHLER *et al.* 2003; STRAUB *et al.* 2005a). Two recent studies provide strong evidence that binding of the MSL complex to the X chromosome of *Drosophila* males increases transcription from almost all X-linked genes (HAMADA *et al.* 2005; STRAUB *et al.* 2005b). The MSL complex is composed of five proteins, encoded by the genes *maleless* (*mle*), *male-specific lethal 1*, 2, and 3 (*msl1*, -2, and -3), and *males absent on first* (*mof*) (FUKUNAGA *et al.* 1975; BELOTE and LUCCHESI 1980; UCHIDA *et al.* 1981; HILFIKER *et al.* 1997). A sixth protein, JIL-1, is required in both sexes but is enriched on the male X chromosome (JIN *et al.* 2000). One of the primary functions of the MSL complex is thought to be acetylation of histone H4 at lysine 16 (H4Ac16), a modification associated with increased expression and attributable to MOF, a histone acetyltransferase (AKHTAR and BECKER 2000; SMITH *et al.* 2000). Two noncoding RNAs, *roX1* and *roX2*, are integral components of the MSL complex and necessary

for exclusive binding to the X chromosome (MELLER and RATTNER 2002). Simultaneous mutation of both *roX* genes causes male lethality, but mutation of a single *roX* gene is without phenotype.

Removal of MSL1 or MSL2 prevents any chromatin binding by the remaining subunits. Mutants of *mle*, *mle3*, or *mof* retain a partial MSL complex at ~35 sites on the X chromosome (GORMAN *et al.* 1995; LYMAN *et al.* 1997; GU *et al.* 1998). By contrast, simultaneous mutation of both *roX* genes prevents the exclusive binding of MSL proteins to the X chromosome. Reduced levels of MSL proteins are retained at some sites on the X chromosome, but they are now detected at a number of ectopic autosomal sites (MELLER and RATTNER 2002; DENG *et al.* 2005). Some of these sites are puffed, a chromatin state usually associated with active transcription. Failure to increase expression of X-linked genes could cause male lethality. However, it is possible that elevated transcription at a small number of autosomal sites contributes to male lethality.

To address global changes in gene expression in *roX1<sup>-</sup>roX2<sup>-</sup>* males, we turned to microarray analysis. Previous studies examining the expression of a limited number of genes in *mle* mutant larvae produced complex, and sometimes conflicting, data (BHADRA *et al.* 1999, 2000, 2005; CHIANG and KURNIT 2003). Two recent studies report a global decrease in X-linked gene expression in *Drosophila* tissue culture cells following RNA interference (RNAi)-mediated *mle2* knockdown (HAMADA *et al.* 2005; STRAUB *et al.* 2005b). We now report that the level

<sup>1</sup>Corresponding author: Department of Biological Sciences, 5047 Gullen Mall, Wayne State University, Detroit, MI 48202.  
E-mail: vmeller@biology.biosci.wayne.edu

of X-linked gene expression is also reduced in *roX1<sup>-</sup> roX2<sup>-</sup>* male larvae. Although enrichment of H4Ac16 can be detected at autosomal sites of ectopic MSL binding in *roX1<sup>-</sup> roX2<sup>-</sup>* males, increased expression was not observed at these sites by either microarray analysis or reverse Northern blotting. Thus, failure to compensate X-linked genes, but not inappropriate overexpression of some autosomal genes, appears to be the source for male lethality upon loss of both *roX* RNAs.

## MATERIALS AND METHODS

**Fly culture and strains:** Flies were maintained at 25° on standard cornmeal–agar fly food in a humidified incubator. The *roX1<sup>es6</sup>*, *roX1<sup>SMC17A</sup>*, and *roX2* mutations have been previously described (MELLER *et al.* 1997; MELLER and RATTNER 2002; DENG *et al.* 2005).

**Microarray expression analysis:** Total RNA was prepared from groups of 50 male third instar larvae by TRIzol (Invitrogen, San Diego), extracted, and purified using the RNeasy kit (QIAGEN, Chatsworth, CA). Three independent RNA preparations for each genotype served as templates for cDNA synthesis. Biotin-labeled probes were produced by *in vitro* transcription of cDNA (protocol at <http://www.Affymetrix.com>). Probes were hybridized to Affymetrix *Drosophila* Genome 2.0 chips (Santa Clara, CA). The Affymetrix *Drosophila* annotation of December 2004 was used to map genes to their cytological locations. Genes were filtered for present/absent calls by a perfect match–mismatch comparison. Autosomal signals were normalized on a chip-by-chip basis to bring their median values to 100. The identical degree of adjustment was used to normalize X-linked transcripts. Changes in expression were determined by comparing the mean signal intensities of genes on arrays hybridized with *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* probes to those hybridized with *roX1<sup>+</sup> roX2<sup>-</sup>* probes. Statistical significance was assessed by performing an unpaired two-tail *t*-test. Complete data for individual genes are supplied in supplemental Table S1 at <http://www.genetics.org/supplemental/>. The raw data can be downloaded from the Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>; GSE3990).

**Quantitative real-time PCR:** One microgram of total RNA was reverse transcribed using random hexamers and ImProm-II reverse transcriptase (Promega, Madison, WI). Real-time PCR was performed as described (DENG *et al.* 2005). *Bigmax*, an autosomal gene involved in transcription regulation, was selected as a reliable transcript for normalization of expression (data not shown). The primers used in this study are presented in supplemental Table S2 at <http://www.genetics.org/supplemental/>.

**Reverse Northern analysis of gene expression:** The following genomic bacterial artificial chromosomes (BAC) clones carrying inserts mapped to autosomal sites of ectopic MSL binding in *roX1<sup>-</sup> roX2<sup>-</sup>* males were restriction digested, separated on gels, and blotted to nylon membranes: BAC from 21B, RPC-98 9.J.20; BAC from 49B, RPC-98 24.H.9; BACs from 50 C/D, RPC-98 6.M.19 and RPC-98 13.P.15; BACs from 53E, RPC-98 32.P.8 and RPC-98 48.A.11; BACs from 57B/C, RPC-98 8.P.5, RPC-98 10.P.16, and RPC-98 33.D.17; BACs from 89B, RPC-98 2.G.19, RPC-98 4.C.7, and RPC-98 6.B.8. cDNA probes were generated from 1 µg of poly(A)<sup>+</sup> RNA isolated from *roX1<sup>es6</sup> roX2<sup>-</sup>* or *roX1<sup>+</sup> roX2<sup>-</sup>* adult males by reverse transcription in the presence of [<sup>32</sup>P]CTP.

**Histology:** Immunohistochemical detection of MSL3, MOF, and H4Ac16 on polytene chromosomes was done as previously described (KELLEY *et al.* 1999). Rabbit anti-H4Ac16 was purchased from Serotec (Raleigh, NC). Goat anti-MSL3 and rabbit anti-MOF were a gift from M. Kuroda.

**Photography:** Visualization and photography were performed with a Zeiss AxioScope 2 fitted with a Qimaging Retiga 2000R digital camera.

## RESULTS

**MOF colocalizes with other MSL proteins in *roX1<sup>-</sup> roX2<sup>-</sup>* males:** A primary function of the MSL complex is modification of chromatin on the X chromosome. The most dramatic manifestation of this is accumulation of H4Ac16, a modification linked to increased transcription, only on the male X chromosome (TURNER *et al.* 1992; BONE *et al.* 1994). In an alternative model for the process of dosage compensation, the MSL complex sequesters MOF, thus preventing its uniform distribution. This is proposed to reduce autosomal expression relative to X-linked gene expression (BIRCHLER *et al.* 2003; STRAUB *et al.* 2005a). Although we do not favor this model for dosage compensation, it is possible that release of the MSL proteins from the X chromosome by mutation of both *roX* genes leads to misregulation of autosomal genes. To estimate the possible extent of autosomal misregulation, we determined the localization and activity of MOF in *roX1<sup>-</sup> roX2<sup>-</sup>* males. Immunostaining of polytene chromosomes from *roX1<sup>-</sup> roX2<sup>-</sup>* mutant larvae reveals disruption of the exclusive X localization of MSL1 and MSL2 (MELLER and RATTNER 2002; DENG *et al.* 2005). These proteins are not uniformly redistributed, but are attracted to a small number of autosomal sites. MOF and MSL3 localization on polytene chromosomes from wild-type and *roX1<sup>-</sup> roX2<sup>-</sup>* mutant male larvae was determined. MOF and MSL3 colocalize on the X chromosome in wild-type males (Figure 1A; also see GU *et al.* 1998). *roX1<sup>-</sup> roX2<sup>-</sup>* males reveal overlapping MOF and MSL3 localization at residual sites along the X chromosome and also at ectopic sites of MSL binding to the chromocenter and autosomes (Figure 1B). This indicates that MOF is not uniformly distributed in a *roX1<sup>-</sup> roX2<sup>-</sup>* genetic background. Colocalization and mapping studies indicate that MSL1, MSL2, MSL3, and MOF continue to associate at autosomal sites of ectopic MSL binding in *roX1<sup>-</sup> roX2<sup>-</sup>* males (supplemental Table S3 at <http://www.genetics.org/supplemental/>).

**Accumulation of H4Ac16 overlaps that of the MSL proteins in *roX1<sup>-</sup> roX2<sup>-</sup>* males:** It is possible that ectopic sites of MSL binding contain genes that are upregulated by the MSL proteins. Acetylation of histones by MOF might contribute to increased transcription or chromatin puffing. In wild-type males, H4Ac16 is highly enriched on the X chromosome (Figure 1A). In *roX1<sup>-</sup> roX2<sup>-</sup>* males, the overall level of acetylation on the X chromosome is sharply reduced, but a number of X-linked sites retaining some MSL proteins show weak acetylation (Figure 1B). The strongest accumulation of H4Ac16 is at the chromocenter, but weak H4Ac16 immunoreactivity is also detected at many autosomal sites




FIGURE 1.—H4Ac16 and MSL colocalize on polytene chromosomes from wild-type and *roX1<sup>-</sup> roX2<sup>-</sup>* males. Chromosome preparations from wild-type and *roX1<sup>ex6</sup> roX2<sup>-</sup>* male larvae were probed with antibodies against MSL3, MOF, and H4Ac16. Patterns of ectopic MSL localization are similar in *roX1<sup>ex6</sup> roX2<sup>-</sup>* and *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* male larvae, but the salivary glands of *roX1<sup>ex6</sup> roX2<sup>-</sup>* produce better polytene chromosomes for immunostaining. (A) Wild-type males. (B) *roX1<sup>ex6</sup> roX2<sup>-</sup>* males. DNA is detected by Hoechst 33258. MSL3 is detected by FITC. MOF and H4Ac16 are detected by Texas Red (TR). An exposure of 40 msec was used for DNA; a 1-sec exposure was used for TR and FITC in wild-type males. Exposure times were lengthened to 4 sec (TR) and 3 sec (FITC) in *roX* mutants. Exposure for the Texas Red channel of row 1 and the FITC channel of rows 2 and 4 in A was longer to demonstrate the absence of cross-reactivity by the secondary antibodies used. X chromosome (X); fourth chromosome (4); chromocenter (Ch).



of MSL binding in *roX1<sup>-</sup> roX2<sup>-</sup>* mutants. This indicates that removal of *roX* RNA does not fully eliminate the ability of the MSL proteins to associate and modify chromatin, potentially leading to increased transcription. The nonuniform distribution of MOF and H4Ac16 suggests that a limited number of autosomal genes are candidates for misregulation in *roX1<sup>-</sup> roX2<sup>-</sup>* males. A few autosomal sites are puffed, attract high levels of the MSL proteins, and display modest enrichment of H4Ac16 in *roX1<sup>-</sup> roX2<sup>-</sup>* males. It is possible that toxic overexpression at these autosomal sites contributes to male lethality. However, the vast majority of autosomal genes do not appear to be targets of MOF activity and are thus likely to remain unchanged in *roX1<sup>-</sup> roX2<sup>-</sup>* males.

**Mutation of both *roX* genes leads to a global reduction in X chromosome expression:** To determine the effect of the loss of *roX1* and *roX2* on gene expression, we performed microarray analysis on *roX1<sup>-</sup> roX2<sup>-</sup>* male larvae. As the changes in expression of most X-linked genes are anticipated to be maximally twofold, efforts were taken to minimize variation in genetic background and to compare X chromosomes that are as similar as possible. *roX1<sup>+</sup> roX2<sup>-</sup>* male larvae were used as the control. These males have full survival without developmental delay and localize the MSL proteins to the X chromosome in a pattern identical to that of wild-type males (MELLER and RATTNER 2002). Use of *roX1<sup>+</sup> roX2<sup>-</sup>* as the control enables a comparison of X chromosomes that are largely identical in sequence. *roX1<sup>SMC17A</sup>* is the most severe *roX1* allele identified to date and appears to be a genetic null (DENG *et al.* 2005). While *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* adults are rarely observed, ~37% of *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* males can be recovered as delayed third instar larvae. Because of its phenotypic severity, the *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* chromosome was used to assess the effect of loss of *roX* RNA on gene expression.

A failure of dosage compensation in flies causes misregulation of a large portion of the genome. This makes normalization of microarrays problematic. After observing the nonuniform H4Ac16 redistribution in *roX1<sup>-</sup> roX2<sup>-</sup>* males, we decided to normalize microarrays to the median autosomal signals (see MATERIALS AND METHODS). This strategy was also based on recent studies documenting reduced X-linked gene expression, rather than increased autosomal expression, following RNAi knockdown of MSL2 in tissue culture cells (HAMADA *et al.* 2005; STRAUB *et al.* 2005b). After normalization and filtering for absent genes, roughly equivalent numbers of X-linked genes were detected in all samples (Table 1). Quantitative PCR (QPCR) on selected genes validated the microarray findings. A total of 18 genes (2 autosomal, 16 X-linked) were tested in three independent measurements. Transcript ratios (*roX1<sup>SMC17A</sup> roX2<sup>-</sup>:roX1<sup>+</sup> roX2<sup>-</sup>*) from QPCR closely matched the average ratios derived from microarrays (supplemental Table S4 at <http://www.genetics.org/supplemental/>). While most changes in expression were modest, two X-linked genes

**TABLE 1**  
Overall expression of X-linked genes decreases in *roX1<sup>-</sup> roX2<sup>-</sup>* males

Array	No. of X-linked genes with present calls	Median intensity	Mean intensity genes
Mutant 1 <sup>a</sup>	2060	131	336
Mutant 2	1997	133	374
Mutant 3	2055	124	347
Control 1 <sup>b</sup>	2055	155	456
Control 2	2011	153	471
Control 3	2036	158	466

<sup>a</sup> Mutant: *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* male larvae.

<sup>b</sup> Control: *roX1<sup>+</sup> roX2<sup>-</sup>* male larvae.

consistently showed dramatic changes. *opt1* is immediately proximal to *roX1*. Expression of *opt1* is reduced fivefold in *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* male larvae, but is similarly decreased in *roX1<sup>SMC17A</sup>* male larvae (data not shown). This is consistent with disruption of an *opt1* regulatory element by the *roX1<sup>SMC17A</sup>* mutation, but not with reduced expression due to the failure of dosage compensation. Expression of *rals* is >10-fold higher in *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* male larvae. This appears due to a low-expressing *rals* allele on the *roX1<sup>+</sup> roX2<sup>-</sup>* (control) chromosome. Examination of *rals* expression in several genotypes is consistent with this interpretation (data not shown). Overall, QPCR analysis strongly supports the changes in gene expression detected by microarray analysis, even when these changes are subtle.

Expression of a substantial number of X-linked genes is decreased as much as twofold in *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* males (Figure 2A). The overall expression of X-linked genes drops by an average of 26% in *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* males (*t*-test,  $P < 0.005$ ; Table 1), with a median decrease of 17% (*t*-test,  $P < 0.005$ ). A plot of the distribution of log<sub>2</sub> ratios (mutant: control) for X-linked and second chromosome genes reveals a peak for the second chromosome close to zero ( $x = -0.054$ ), while the peak for X-linked genes is shifted left ( $x = -0.291$ ; Figure 2B). The distribution of third chromosome genes is similar to that of the second chromosome genes (data not shown). ANOVA for multiple comparisons rejects the null hypothesis that the distributions of the X chromosome and the second chromosome are the same ( $P$ -value  $< 10^{-20}$ ). These observations indicate a widespread decrease in expression of X-linked genes in *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* males.

A distinct bias toward modestly decreased expression of X-linked genes is detected in *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* males (Table 2). Selection of genes with changes of 1.5- to 1.99-fold or 2- to 2.99-fold reveals a similar proportion of autosomal genes showing slight decrease or increase in expression. However, X-linked genes that decrease slightly are dramatically overrepresented at the expense




FIGURE 2.—Expression of the male X chromosome is decreased in *roX1<sup>-</sup> roX2<sup>-</sup>* males. (A) Expression of X-linked genes (solid dots) and autosomal genes (shaded dots) in *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* and *roX1<sup>+</sup> roX2<sup>-</sup>* male larvae. Log intensity values for each genotype are indicated on the axes. Diagonal lines indicate ratios of 0.5, 1, and 2. (B) Distribution of the log<sub>2</sub> ratios for genes detected on *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* and *roX1<sup>+</sup> roX2<sup>-</sup>* arrays. X chromosome (dotted line) and second chromosome (solid line). Genes with present calls in at least two of three mutant and control arrays were plotted.

of those with modest increases. In contrast, similar percentages of X-linked and autosomal genes increase or decrease by  $\geq 3$ -fold. These more dramatic changes in expression are likely attributable to the indirect effects of dosage compensation failure, such as developmental delay, reduced size, and the overall poor health of *roX1<sup>SMC17A</sup> roX2<sup>-</sup>* male larvae.

***roX1<sup>SMC17A</sup> roX2<sup>-</sup>* males display gene misregulation similar to that in male cells and larvae lacking MSL proteins:** This analysis of *roX1<sup>-</sup> roX2<sup>-</sup>* males is the first

genomewide study of expression after the disruption of dosage compensation in *Drosophila* larvae. However, several studies have previously looked at the regulation of a small number of genes in larvae carrying *msl* mutations, and two recent studies have examined gene expression in male S2 cells following *msl2* RNAi knockdown. This provides the opportunity to compare the effect of disrupting different components of the dosage compensation system on the expression of X-linked genes. Knockdown of *msl2* in S2 cells is particularly valuable as males carrying mutations in *msl2* rarely survive into the third instar, the stage at which *roX1<sup>-</sup> roX2<sup>-</sup>* males are collected.

Direct targets of MSL binding were identified, and absolute expression changes for these genes were documented in *msl2* RNAi knockdown S2 cells (STRAUB *et al.* 2005b). Three individual X-linked genes that are bound by the MSL proteins *CG14804*, *mRpl16*, and *Arm* were reduced in expression by  $\sim 40\%$  upon the depletion of *msl2* in S2 cells. These same genes are reduced by  $\sim 30\text{--}40\%$  in our analysis. A global comparison of gene expression between S2 cells lacking MSL2 (HAMADA *et al.* 2005) and *roX1<sup>-</sup> roX2<sup>-</sup>* male larvae (this report) was also done. About twice as many genes are detected in male larvae as in S2 cells, presumably because larvae have differentiated tissues expressing genes that are silent in tissue culture cells. However, transcripts detected in both data sets will be enriched for housekeeping and essential genes that are steadily expressed throughout fly development. Most autosomal genes were unchanged in both data sets (Figure 3A). In contrast, of a total of 1112 X-linked genes present in both data sets, 858 decreased in both (Figure 3B). While the overall level of decrease of X-linked gene expression was similar in S2 cells treated with double-stranded RNA to *msl2* and in *roX1<sup>-</sup> roX2<sup>-</sup>* male larvae, the response in larvae was more heterogeneous than in S2 cells (Figure 3B). This heterogeneity is most apparent in the weakly expressed genes (supplemental Figure S1, A and B, at <http://www.genetics.org/supplemental/>). X-linked genes with high expression tend to be uniformly affected in both studies (supplemental Figure S1C at <http://www.genetics.org/supplemental/>). This may indicate that heavily transcribed genes are more dependent upon

TABLE 2

X-linked genes are biased toward slightly decreased expression in *roX1<sup>-</sup> roX2<sup>-</sup>* males

	Fold increase			Fold decrease		
	1.5–1.99	2.0–2.99	$\geq 3$	1.5–1.99	2.0–2.99	$\geq 3$
X-linked genes	38 <sup>a</sup> (2.0)	19 (1.0)	13 (0.7)	335 (17.8)	158 (8.4)	21 (1.1)
Autosomal genes	505 (4.9)	162 (1.6)	68 (0.7)	967 (9.5)	332 (2.7)	62 (0.6)

The percentage of X-linked or autosomal genes is indicated in parentheses. Only genes present on at least two of three arrays from each genotype were considered (1884 of 3090 X-linked genes and 10,185 of 15,892 autosomal genes).

<sup>a</sup> Genes displaying expression changes (*t*-test *P*-value  $< 0.05$ ) in the indicated ranges were determined.




FIGURE 3.—X-linked genes display similar changes in *roX1<sup>-</sup> roX2<sup>-</sup>* males and MSL2-depleted S2 cells. (A) Log<sub>2</sub> ratio of change in expression for autosomal genes in response to loss of both *roX* genes (*x*-axis; this study) plotted against log<sub>2</sub> ratio of change in response to MSL2 depletion in S2 cells (*y*-axis; HAMADA *et al.* 2005). (B) Log<sub>2</sub> ratio of change in expression of X-linked genes in response to loss of both *roX* genes plotted against log<sub>2</sub> ratio of change in S2 cells in response to MSL2 depletion. The number of X-linked genes in each quadrant is indicated. Only genes detected on all 12 arrays contributed to this analysis. Raw microarray data from HAMADA *et al.* (2005) have been renormalized using the methodology of this study (see MATERIALS AND METHODS).

the activity of the MSL complex, but it could also reflect more accurate measurement of abundant transcripts.

Previous studies of *msl* or *Sxl* mutant larvae have documented the response of a small number of genes to dosage compensation failure (BHADRA *et al.* 2000; CHIANG and KURNIT 2003). We examined expression changes of these genes upon loss of *roX* RNAs. Of 20 genes examined in *mle<sup>pm18</sup>* and *Sxl<sup>M</sup>* male larvae by Northern blot analysis, 8 display similar trends in *roX1<sup>-</sup> roX2<sup>-</sup>*,

*mle<sup>pm18</sup>*, and *Sxl<sup>M</sup>* males (supplemental Table S5 at <http://www.genetics.org/supplemental/>; BHADRA *et al.* 2000). Considerably more agreement is found between our study and a previous analysis of *msl* mutants that used a sensitive RT-QPCR assay (CHIANG and KURNIT 2003). Of the 12 examined genes, 9 showed the same trend in *roX1<sup>-</sup> roX2<sup>-</sup>*, *mle<sup>1</sup>*, and *mof<sup>1</sup>* male larvae (supplemental Table S5 at <http://www.genetics.org/supplemental/>). We also observed coordinated expression changes of *BR-C* and *Sgs* in *roX1<sup>-</sup> roX2<sup>-</sup>* males, consistent with studies showing that *BR-C* mutations blocked induction of the *Sgs* genes (supplemental Table S5 at <http://www.genetics.org/supplemental/>; GUAY and GUILD 1991; KARIM *et al.* 1993; CHIANG and KURNIT 2003). While the agreement between these studies is suggestive, it is worth noting that both *msl* and *roX1<sup>-</sup> roX2<sup>-</sup>* mutants are developmentally delayed. A broad spectrum of genes normally expressed in late larval development, such as the *BR-C* and *Sgs* genes, may be affected by nonspecific mechanisms.

**Elevated expression is not detected at ectopic sites of MSL binding:** Strong MSL binding and enrichment for H4Ac16 at ectopic autosomal sites might lead to overexpression of a few autosomal genes in *roX1<sup>-</sup> roX2<sup>-</sup>* males. Changes in gene expression were plotted against chromosomal position for four of the most striking autosomal sites of MSL accumulation (21B, 50D, 53E, and 89B). While there is some variation in expression across each of these regions, none reveals a dramatic increase in expression (supplemental Figure S2 at <http://www.genetics.org/supplemental/>). A few genes within these sites display approximately twofold increases in *roX1<sup>-</sup> roX2<sup>-</sup>* males, but similar or more pronounced changes occur in surrounding regions that do not attract MSL proteins. To further explore this question, BACs covering six sites that consistently attract high levels of MSL proteins in *roX1<sup>-</sup> roX2<sup>-</sup>* males were examined by reverse Northern blotting. mRNA isolated from *roX1<sup>+</sup> roX2<sup>-</sup>* and escaping *roX1<sup>ex6</sup> roX2<sup>-</sup>* adult males was reverse transcribed to generate radiolabeled probes. These probes were hybridized to blots of BAC restriction fragments. No BAC reveals a band with notably stronger hybridization to cDNA probes from *roX1<sup>ex6</sup> roX2<sup>-</sup>* adult males (supplemental Figure S3 at <http://www.genetics.org/supplemental/>). While microarray and reverse Northern blotting experiments do not rule out the possibility that a single gene is modestly increased in expression by MSL binding, they do indicate that massive overexpression of a few autosomal genes does not occur at puffed sites that recruit the MSL proteins in *roX1<sup>-</sup> roX2<sup>-</sup>* males.

## DISCUSSION

Numerous studies have implicated the *roX* RNAs in dosage compensation of the male X chromosome of

*Drosophila*. However, this study is the first to address the effect of the elimination of the *roX* transcripts on gene expression. We find a chromosome-wide decrease in X-linked gene expression, consistent with sharply reduced localization of the MSL proteins on the X chromosome in *roX1<sup>-</sup> roX2<sup>-</sup>* males (DENG *et al.* 2005). This reduction is not as dramatic as would be anticipated from a complete failure of dosage compensation. It is possible that the minor enrichment of the MSL protein and H4Ac16 that continue to be detectable on the X chromosome of all *roX1<sup>-</sup> roX2<sup>-</sup>* males provides some compensation. However, the magnitude of decrease (~26%) is comparable to that achieved by knockdown of MSL2 in cells using RNAi (~30%; HAMADA *et al.* 2005; STRAUB *et al.* 2005b). As removal of MSL2 prevents any chromatin binding by the remaining MSL proteins, it appears likely that this level of decrease represents the full effect of compensation failure. The modesty of this effect suggests that, when the *roX* and MSL mechanism of dosage compensation is disabled, a partial equalization of X-linked gene expression is achieved through the activity of a backup mechanism. The nature of a potential backup system is unknown, but the response to aneuploidy, which partially compensates for large chromosomal deletions, is a likely candidate (BIRCHLER *et al.* 2001). There is no reason to suspect that the response to reduced expression of the entire X chromosome, which would mimic chromosomal aneuploidy, would be different than the response to aneuploidy for an autosome. Interestingly, the aneuploidy response has been suggested to play a role in normal dosage compensation (BIRCHLER *et al.* 2003).

While most X-linked genes do appear to be compensated by upregulation in males, it has been proposed that a few are compensated in females through a reduction in translation. This is based on the observation that Sex lethal (SXL) directs compensation of the *run* (*run*) gene, but not through the action of the MSL proteins (GERGEN 1987; BERNSTEIN and CLINE 1994). The discovery that transcripts with multiple SXL-binding sites were almost exclusively X-linked strengthened the idea of a female component of compensation acting by SXL repression of translation (KELLEY *et al.* 1995). Intriguingly, *run* is one of the X-linked genes with SXL-binding sites. The *run* gene does not accumulate H4Ac16 in males, and *run* expression is not decreased in *roX1<sup>-</sup> roX2<sup>-</sup>* or *msl* males (supplemental Tables S4 and S5 at <http://www.genetics.org/supplemental/>; SMITH *et al.* 2001). While this suggests that *run* is likely to be compensated in females by SXL, about half of the X-linked genes that display multiple SXL-binding sites do decrease in *roX1<sup>-</sup> roX2<sup>-</sup>* males, indicating at least a partial regulation by the MSL complex (data not shown).

No dramatic increase in expression was observed at ectopic sites of MSL binding on autosomes, in spite of puffing and accumulation of H4Ac16 at some of these sites in *roX1<sup>-</sup> roX2<sup>-</sup>* males. A few of these autosomal sites

display weak staining of the MSL proteins and enrichment of H4Ac16 even in wild-type males (GORMAN *et al.* 1995; MELLER and RATTNER 2002). It is possible that this represents genes already under the control of the MSL proteins. If this is indeed the case, further MSL binding and H4Ac16 enrichment might be superfluous. Alternatively, a modest increase might occur, but this increase is so slight that it is indistinguishable from variations in flanking regions of the chromosome. This is somewhat at odds with the dramatic puffing at many of these sites, a condition typically associated with strong transcription (BONNER and PARDUE 1977). It is possible that genes not represented on microarrays, such as heterochromatic genes or those producing noncoding RNA, are increased in expression. Nonpolyadenylated transcripts would also escape detection in reverse Northern blots with probes generated from poly(A)<sup>+</sup> RNAs. The idea that the MSL proteins might be attracted to the sites of synthesis of noncoding transcripts, many of which have been identified in *Drosophila*, is plausible (INAGAKI *et al.* 2005). However, the sites of ectopic MSL binding in *roX1<sup>-</sup> roX2<sup>-</sup>* males do not correspond to known noncoding RNAs.

The site of strongest MSL binding and H4Ac16 accumulation on chromosome preparations from *roX1<sup>-</sup> roX2<sup>-</sup>* males is the chromocenter. It is possible that ectopic MSL binding at the chromocenter is due to interaction of the MSL proteins with other proteins. It has been shown that heterochromatin protein 1 (HP1), a major component of heterochromatin, is modestly enriched on the male X chromosome (DE WIT *et al.* 2005). Overexpression of MSL1 and MSL2 leads to ectopic binding of the MSL proteins at the chromocenter (DEMAKOVA *et al.* 2003). These observations suggest an affinity between heterochromatin proteins, possibly HP1 itself, and the MSL proteins. In this study, transcription from the chromocenter, which is primarily heterochromatic, was not specifically addressed. Annotation of heterochromatic genes has lagged behind euchromatic regions of the genome, and these are underrepresented on microarrays (*Drosophila* Heterochromatin Genome Project, <http://www.dhgp.org/>; HOSKINS *et al.* 2002).

The failure to identify autosomal transcripts that increase dramatically upon ectopic localization of the MSL complex reinforces the idea that the ultimate cause of male lethality is failure to express the entire X chromosome at appropriate levels. Although many genes are toxic upon massive overexpression, there is only a single locus, *Triplotelethal* (*Tpl*), for which appropriate dosage is so critical that duplication results in death (LINDSLEY *et al.* 1972). We have not detected enhanced MSL binding or increased expression at the *Tpl* locus in *roX1<sup>-</sup> roX2<sup>-</sup>* larvae (data not shown). This suggests that minor disruptions of autosomal expression are unlikely to contribute to the lethality of *roX1<sup>-</sup> roX2<sup>-</sup>* males.



We thank the Applied Genomics and Technology Center at Wayne State University for expert assistance in microarray studies and Bethany Strunk and L. Pile for advice on quantitative PCR. We also thank Ying Huang and C. Freeman for contributing their time and expertise to data analysis. Antibodies were a gift from M. I. Kuroda. This study was supported by start-up funds from Wayne State University and National Institutes of Health grant GM5 8427.

## LITERATURE CITED

- AKHTAR, A., and P. BECKER, 2000 Activation of transcription through histone H4 acetylation by MOF, an acetyl transferase essential for dosage compensation in *Drosophila*. *Mol. Cell* **5**: 367–375.
- BELOTE, J. M., and J. C. LUCCHESI, 1980 Male-specific lethal mutations of *Drosophila melanogaster*. *Genetics* **96**: 165–186.
- BERNSTEIN, M., and T. W. CLINE, 1994 Differential effects of Sex-lethal mutations on dosage compensation early in *Drosophila* development. *Genetics* **136**: 1051–1061.
- BHADRA, U., M. PAL-BHADRA and J. A. BIRCHLER, 1999 Role of the male specific lethal (msl) genes in modifying the effects of sex chromosomal dosage in *Drosophila*. *Genetics* **152**: 249–268.
- BHADRA, U., M. PAL-BHADRA and J. A. BIRCHLER, 2000 Histone acetylation and gene expression analysis of sex lethal mutants in *Drosophila*. *Genetics* **155**: 753–763.
- BHADRA, M. P., U. BHADRA, J. KUNDU and J. A. BIRCHLER, 2005 Gene expression analysis of the function of the male-specific lethal complex in *Drosophila*. *Genetics* **169**: 2061–2074.
- BIRCHLER, J. A., U. BHADRA, M. P. BHADRA and D. L. AUGER, 2001 Dosage-dependent gene regulation in multicellular eukaryotes: implications for dosage compensation, aneuploid syndromes, and quantitative traits. *Dev. Biol.* **234**: 275–288.
- BIRCHLER, J. A., M. PAL-BHADRA and U. BHADRA, 2003 Dosage dependent gene regulation and the compensation of the X chromosome in *Drosophila* males. *Genetica* **117**: 179–190.
- BONE, J. R., J. LAVENDER, R. RICHMAN, M. J. PALMER, B. M. TURNER *et al.*, 1994 Acetylated histone H4 on the male X chromosome is associated with dosage compensation in *Drosophila*. *Genes Dev.* **8**: 96–104.
- BONNER, J. J., and M. L. PARDUE, 1977 Polytene chromosome puffing and in situ hybridization measure different aspects of RNA metabolism. *Cell* **12**: 227–234.
- CHIANG, P. W., and D. M. KURNIT, 2003 Study of dosage compensation in *Drosophila*. *Genetics* **165**: 1167–1181.
- DEMAKOVA, O. V., I. V. KOTLIKOVA, P. R. GORDADZE, A. A. ALEKSEYENKO, M. I. KURODA *et al.*, 2003 The MSL complex levels are critical for its correct targeting to the chromosomes in *Drosophila melanogaster*. *Chromosoma* **112**: 103–115.
- DENG, X., B. P. RATTNER, S. SOUTER and V. H. MELLER, 2005 The severity of roX1 mutations is predicted by MSL localization on the X chromosome. *Mech. Dev.* **122**: 1094–1105.
- DE WIT, E., F. GREIL and B. VAN STEENSEL, 2005 Genome-wide HP1 binding in *Drosophila*: developmental plasticity and genomic targeting signals. *Genome Res.* **15**: 1265–1273.
- FUKUNAGA, A., A. TANAKA and K. OISHI, 1975 *Maleless*, a recessive autosomal mutant of *Drosophila melanogaster* that specifically kills male zygotes. *Genetics* **81**: 135–141.
- GERGEN, J. P., 1987 Dosage compensation in *Drosophila*: evidence that *daughterless* and *Sex-lethal* control X chromosome activity at the blastoderm stage of embryogenesis. *Genetics* **117**: 477–485.
- GORMAN, M., A. FRANKE and B. S. BAKER, 1995 Molecular characterization of the male-specific lethal-3 gene and investigations of the regulation of dosage compensation in *Drosophila*. *Development* **121**: 463–475.
- GU, W., P. SZAUTER and J. C. LUCCHESI, 1998 Targeting of MOF, a putative histone acetyl transferase, to the X chromosome of *Drosophila melanogaster*. *Dev. Genet.* **22**: 56–64.
- GUAY, P. S., and G. M. GUILD, 1991 The ecdysone-induced puffing cascade in *Drosophila* salivary glands: a Broad-Complex early gene regulates intermolt and late gene transcription. *Genetics* **129**: 169–175.
- HAMADA, F. N., P. J. PARK, P. R. GORDADZE and M. I. KURODA, 2005 Global regulation of X chromosomal genes by the MSL complex in *Drosophila melanogaster*. *Genes Dev.* **19**: 2289–2294.
- HILFIKER, A., D. HILFIKER-KLEINER, A. PANNUTI and J. C. LUCCHESI, 1997 mof, a putative acetyl transferase gene related to the Tip60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in *Drosophila*. *EMBO J.* **16**: 2054–2060.
- HOSKINS, R. A., C. D. SMITH, J. W. CARLSON, A. B. CARVALHO, A. HALPERN *et al.*, 2002 Heterochromatic sequences in a *Drosophila* whole-genome shotgun assembly. *Genome Biol.* **3**: RESEARCH0085.
- INAGAKI, S., K. NUMATA, T. KONDO, M. TOMITA, K. YASUDA *et al.*, 2005 Identification and expression analysis of putative mRNA-like non-coding RNA in *Drosophila*. *Genes Cells* **10**: 1163–1173.
- JIN, Y., Y. WANG, J. JOHANSEN and K. M. JOHANSEN, 2000 JIL-1, a chromosomal kinase implicated in regulation of chromatin structure, associates with the male specific lethal (MSL) dosage compensation complex. *J. Cell Biol.* **149**: 1005–1010.
- KARIM, F. D., G. M. GUILD and C. S. THUMMEL, 1993 The *Drosophila* Broad-Complex plays a key role in controlling ecdysone-regulated gene expression at the onset of metamorphosis. *Development* **118**: 977–988.
- KELLEY, R. L., I. SOLOVYEV, L. M. LYMAN, R. RICHMAN, V. SOLOVYEV *et al.*, 1995 Expression of msl-2 causes assembly of dosage compensation regulators on the X chromosomes and female lethality in *Drosophila*. *Cell* **81**: 867–877.
- KELLEY, R. L., V. H. MELLER, P. R. GORDADZE, G. ROMAN, R. L. DAVIS *et al.*, 1999 Epigenetic spreading of the *Drosophila* dosage compensation complex from roX RNA genes into flanking chromatin. *Cell* **98**: 513–522.
- LINDSLEY, D. L., L. SANDLER, B. S. BAKER, A. T. CARPENTER, R. E. DENELL *et al.*, 1972 Segmental aneuploidy and the genetic gross structure of the *Drosophila* genome. *Genetics* **71**: 157–184.
- LYMAN, L. M., K. COPPS, L. RASTELLI, R. L. KELLEY and M. I. KURODA, 1997 *Drosophila* male-specific lethal-2 protein: structure/function analysis and dependence on MSL-1 for chromosome association. *Genetics* **147**: 1743–1753.
- MELLER, V. H., and B. P. RATTNER, 2002 The roX genes encode redundant male-specific lethal transcripts required for targeting of the MSL complex. *EMBO J.* **21**: 1084–1091.
- MELLER, V. H., K. H. WU, G. ROMAN, M. I. KURODA and R. L. DAVIS, 1997 roX1 RNA paints the X chromosome of male *Drosophila* and is regulated by the dosage compensation system. *Cell* **88**: 445–457.
- SMITH, E. R., A. PANNUTI, W. GU, A. STEURNAGEL, R. G. COOK *et al.*, 2000 The *Drosophila* MSL complex acetylates histone H4 at lysine 16, a chromatin modification linked to dosage compensation. *Mol. Cell Biol.* **20**: 312–318.
- SMITH, E. R., C. D. ALLIS and J. C. LUCCHESI, 2001 Linking global histone acetylation to the transcription enhancement of X-chromosomal genes in *Drosophila* males. *J. Biol. Chem.* **276**: 31483–31486.
- STRAUB, T., I. K. DAHLSEVEN and P. B. BECKER, 2005a Dosage compensation in flies: mechanism, models, mystery. *FEBS Lett.* **579**: 3258–3263.
- STRAUB, T., G. D. GILFILLAN, V. K. MAIER and P. B. BECKER, 2005b The *Drosophila* MSL complex activates the transcription of target genes. *Genes Dev.* **19**: 2284–2288.
- TURNER, B. M., A. J. BIRLEY and J. LAVENDER, 1992 Histone H4 isoforms acetylated at specific lysine residues define individual chromosomes and chromatin domains in *Drosophila* polytene nuclei. *Cell* **69**: 375–384.
- UCHIDA, S., T. UENOYANA and K. OISHI, 1981 Studies on the sex-specific lethals of *Drosophila melanogaster*. *Jpn. J. Genet.* **56**: 523–527.